Immune Provides Financial Information in Response to Nasdaq First North Stockholm

Immune Pharmaceuticals Inc. (the "Company") announced today that on October 19, 2017, Nasdaq First North Stockholm (the "Exchange") halted trading in the Company's shares pending the Company's providing public disclosure in Sweden regarding its current financial position.

Immune Pharmaceuticals Inc. announces pricing of $18,000,000 public offering of convertible preferred stock and warrants

ENGLEWOOD CLIFFS, N.J., (BUSINESS WIRE) - Immune Pharmaceuticals Inc. ("Immune") (NASDAQ: IMNP) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, today announced the pricing of an underwritten public offering of units for gross proceeds of $18,000,000, which excludes underwriting discounts and commissions and offering expenses payable by Immune.

Immune Pharmaceuticals Announces Presentation at The Liver Meeting 2017

Poster demonstrates activity of anti-eotaxin-1 antibodies in an animal model of immune-mediated hepatitis

Immune Pharmaceuticals Announces Positive Results from Ongoing Phase 2 Trial of Bertilimumab in Bullous Pemphigoid

Results from six subjects demonstrate a large and statistically significant reduction in bullous pemphigoid activity despite aggressive prednisone tapering, with no serious adverse events.

Immune Pharmaceuticals Provides R&D and Business Update and Summary of Recent Financial Highlights

Immune Pharmaceuticals Inc. (NASDAQ: IMNP) ("Immune" or the "Company") provided the following R&D and business update and summary of recent financial highlights.

Immune Pharmaceuticals, Inc. Issues Letter to Shareholders

Immune Pharmaceuticals Inc. (NASDAQ; IMNP) a clinical stage biopharmaceutical company specializing in the development of novel targeted therapeutic agents in the fields of immuno-inflammation, dermatology and immuno-oncology, issued the following Letter to Shareholders.

Immune Pharmaceuticals Provides Update on Plan to Implement a Spin-off of Cytovia into a Separate Publicly Traded Oncology Company

Immune shareholders to receive additional pro rata shares in Cytovia

Cytovia Inc, Immune Pharmaceuticals' Oncology Subsidiary, Enters into a Definitive Agreement with Pint Pharma for the Licensing and Commercialization of Ceplene® in Latin America

Cytovia Inc. ("Cytovia") the oncology subsidiary of Immune Pharmaceuticals Inc. (NASDAQ: IMNP) ("Immune") announced today that it has entered into a licensing agreement with Pint Pharma International S.A. ("Pint") a pharmaceutical company focused on Latin America and other markets, for the marketing and distribution of Ceplene throughout Latin America (the "territory"). Pint Gmbh will separately enter into an investment agreement, which will lead to an investment of $4 million into Cytovia. Dr. Massimo Radaelli, Executive Chairman of Pint, will also join the board of Cytovia upon completion of the investment and effective spin off of Cytovia from Immune.

Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Sturegatan 32
114 36 Stockholm

08-692 21 90

Kontakta oss

Vill du veta mer om beQuoted och våra tjänster så fyll i nedanstånde uppgifter och tryck skicka.

En av våra rådgivare kontaktar dig inom kort.

Namn: Telefon: E-postadress: Meddelande: